Paraneoplastic cerebellar degeneration with anti-Yo antibodies associated with metastatic uveal melanoma

Sara Valpione, Marco Zoccarato, Raffaele Parrozzani, Jacopo Pigozzo, Bruno Giometto, Francesco Laveder, Camillo Aliberti, Vanna Chiarion-Sileni

Research output: Contribution to journalArticlepeer-review


Paraneoplastic cerebellar degeneration (PCD) is characterized by subacute development of pancerebellar dysfunction as a remote effect of a systemic cancer and usually develops in patients affected by gynecological tumors. Uveal melanoma is a very rare disease with a severe prognosis. A 58-year-old man affected by uveal melanoma developed anti-Yo positive paraneoplastic cerebellar degeneration (PCD) 42 months after the initial diagnosis. The onset and worsening of the neurological symptoms were parallel to the course of liver metastasis. To our knowledge this is the first case of PCD in a patient with uveal melanoma. We speculate that the cerebellar degeneration-related protein 2 (CDR2), to which the anti-Yo antibodies are directed, may have been expressed in melanoma cells and conferred proliferative advantage to the disease.

Original languageEnglish
Pages (from-to)210-212
Number of pages3
JournalJournal of the Neurological Sciences
Issue number1-2
Publication statusPublished - Dec 15 2013


  • Anti-Yo antibodies
  • Cancer
  • CDR
  • Paraneoplastic cerebellar degeneration
  • Paraneoplastic syndrome
  • Uveal melanoma

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology


Dive into the research topics of 'Paraneoplastic cerebellar degeneration with anti-Yo antibodies associated with metastatic uveal melanoma'. Together they form a unique fingerprint.

Cite this